{"id":176479,"name":"ALNYLAM PHARMACEUTICALS","slug":"alnylam-pharmaceuticals","state":"MA","country":"United States of America","description":"Biopharmaceutical company","totalSpending":1490000,"filings":30,"yearlySpending":[{"year":2018,"income":60000},{"year":2019,"income":190000},{"year":2020,"income":200000},{"year":2021,"income":220000},{"year":2022,"income":220000},{"year":2023,"income":220000},{"year":2024,"income":240000},{"year":2025,"income":140000}],"issues":[{"code":"MMM","display":"Medicare/Medicaid"},{"code":"HCR","display":"Health Issues"}],"firms":["THE MCMANUS GROUP"],"lobbyists":["JOHN MCMANUS","BARRETT THORNHILL","CHRISTINA HOCHUL","ALANNA TEMME","LAWREN GEER"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","HOUSE OF REPRESENTATIVES","Office of Management & Budget (OMB)","SENATE","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Reimbursement and access to novel therapeutics based on RNA interference and related administration costs.","Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340.","Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act","Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892 - Bipartisan Budget Act","Implementation of CY 2019 Home Health Prospective Payment System Rate Update/ Home Infusion Therapy Proposed Rule, 83 Fed. Reg. 32340. Implementation of Sec. 50401 of H.R. 1892, the Bipartisan Budget "]}